
Wegovy Pill (semaglutide) vs. Foundayo (orforglipron) for Weight Loss
The U.S. Food and Drug Administration has now approved two once-daily oral GLP‑1–pathway therapies for chronic weight management: Wegovy pill (oral semaglutide 25 mg, peptide-based) from Novo Nordisk and Foundayo (orforglipron, non‑peptide small molecule) from Eli Lilly and Company. Wegovy pill was approved in late December 2025 with launch in early January 2026, while Foundayo was approved April 1, 2026 via an ultra‑accelerated pathway tied to a national-priority voucher pilot.







